has received two unrestricted research grants from Novo Nordisk A/S for two clinical studies investigating the effects of GLP-1RAs in antipsychotic-treated prediabetic patients with schizophrenia
When you begin a semaglutide-based weight loss program at our practice, our team of experienced providers will start you on a low dose, gradually increasing it over several weeks to reduce the risk of side effects
Possible effects include nausea, reflux, constipation, or fatigue all of which are monitored closely and managed conservatively
But even low doses appear to have a positive impact on opioid craving reduction, which is promising for managing potential side effects like nausea or excess weight loss
Positive ROI accumulation A proven track record of delivered, measurable health improvements and cost savings, providing partners with a 4.1X ROI over a three-year period
Notably, the subsequent settlement between Novo Nordisk and Hims & Hers (under which Hims & Hers will sell branded FDA-approved semaglutide products while ceasing its advertising of compounded alternatives) suggests that at least some market participants are already adapting to this new reality